On this page
Stroke has been studied more carefully than most indications here, including a randomised trial and a meta-analysis, and the results are instructive precisely because they are mixed. Ischaemic stroke and stem cell therapy is a genuine research field where the honest summary is “not yet”, not “no”.
What an ischaemic stroke does
A blood vessel supplying part of the brain is blocked. Tissue downstream is deprived of oxygen and dies, and the functions that region controlled are lost or impaired.
Around the dead core sits the penumbra — tissue that is damaged but potentially salvageable if blood flow is restored quickly. That is the target of emergency treatment, and it is why the phrase “time is brain” governs how stroke units are run.
Afterwards, recovery comes partly from resolution of swelling and partly from neuroplasticity, as surviving networks take on functions previously handled elsewhere. Most of that happens in the first three to six months.
That natural trajectory is the reason uncontrolled studies in this condition are so hard to read. Improvement during the first year would have happened anyway in many patients, and without a comparison group there is no way to separate the treatment from the calendar.
What established treatment achieves
In the acute phase, thrombolysis and mechanical thrombectomy can restore blood flow and dramatically change outcomes. Both are exquisitely time-dependent, which is why stroke services are organised around speed.
Afterwards, secondary prevention — blood pressure, anticoagulation where indicated, lipids, smoking, diabetes — reduces the risk of another stroke, which is the single largest threat to someone who has had one.
And rehabilitation, which is where functional recovery is actually built. Intensity and timing matter, and access to enough of it is the limiting factor for most people — see the research library for how that compares with what is being sold alongside it.
Why cells are studied for this
Not to replace dead brain tissue, which nothing currently does. The proposed mechanisms are modulating post-stroke inflammation, supporting the penumbra, encouraging new blood vessel formation, and enhancing the neuroplasticity that drives natural recovery.
That last one is the more interesting proposition: not repair, but amplification of a recovery process that already happens.
It also implies timing matters, and that a treatment given years afterwards is targeting a window that has largely closed.
Worth being clear about what that would mean if it worked: a somewhat better outcome than rehabilitation alone, not a return to how things were. Nobody studying this is claiming otherwise, whatever is claimed on the way to selling it.
What the trials found
A randomised trial assessed intravenous MSCs for ischaemic stroke — Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke.
A meta-analysis examined intravenous MSCs for motor recovery specifically — Efficacy of Intravenous Mesenchymal Stem Cells for Motor Recovery After Ischemic Stroke.
A 2025 study compared intrathecal against intravenous delivery in stroke sequelae — Intrathecal versus intravenous umbilical cord mesenchymal stem cells for ischemic stroke sequelae — a comparison that matters because route is otherwise assumed rather than tested.
Work in this area goes back two decades — Autologous mesenchymal stem cell transplantation in stroke patients — which is itself worth noting: twenty years of study without an established treatment is information about how hard the problem is.
How to read “mixed results”
Some trials report modest improvements in motor scores; others find no significant difference. Meta-analysis in this situation tends to produce a small pooled effect with wide confidence intervals.
That pattern is characteristic of either a small real effect or no effect plus publication bias, and distinguishing between those requires larger trials than currently exist.
It is a more honest picture than either camp usually presents — see what the evidence levels mean.
The trials also differ in when cells were given, by which route, at what dose and in whom, so a pooled figure is averaging across genuinely different interventions. That is a limitation the reviews themselves state and marketing summaries omit.
Timing, again
Most natural recovery occurs in the first three to six months. A treatment proposing to enhance neuroplasticity is most plausible within that window, and considerably less so once the deficit has been stable for years.
People travelling abroad for treatment are usually well past it, often years post-stroke with a stable deficit.
Ongoing research is looking at upper limb recovery specifically — Regenerative therapies for upper limb functional recovery after stroke: study protocol of a randomized trial — and a study protocol is a study that has not reported yet.
Risks in this population
Stroke patients often have significant cardiovascular disease, which affects how well they tolerate any procedure.
Intravenous cell infusion carries a theoretical thrombotic risk that matters more in a population already prone to clotting, and many are anticoagulated, which changes the risk of any invasive procedure.
Travel itself carries risk here — long flights, immobility and time-zone disruption to medication schedules — see adverse events and international patients.
What would actually be worth doing
Maximising rehabilitation intensity, which reliably improves function and which most people do not get enough of.
Optimising secondary prevention, because a second stroke is the largest threat and is substantially preventable. Blood pressure control alone does more for that risk than anything discussed on this page, and it is available everywhere.
And considering a registered trial, where treatment is monitored and the result contributes to answering the question — see the main treatment page.
Cognitive decline and Parkinson’s disease cover the neighbouring neurological evidence, which is graded separately and for different reasons.
Frequently asked questions
Can stem cells repair brain damage from a stroke?
Nothing currently replaces dead brain tissue, and no treatment anywhere does. The proposed mechanisms are about supporting recovery processes the brain already runs, not rebuilding the area that died.
Is there randomised evidence?
Yes, including a randomised trial of intravenous MSCs and a meta-analysis on motor recovery. Results are mixed, with small effects and wide confidence intervals.
Does it matter how long ago my stroke was?
Probably a great deal. Most natural recovery happens in the first three to six months, and the plasticity rationale is weakest years afterwards.
Which route is best?
Not established. A 2025 study compared intrathecal against intravenous delivery, which is more than most indications have.
Why has twenty years of research produced no treatment?
Because it is a hard problem. That history is itself worth weighing against any clinic presenting the question as settled.
What helps most after a stroke?
Rehabilitation intensity and secondary prevention. Both are evidenced, both are underprovided, and neither requires a flight.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.